| Hematopoietic stem cell transplantation is effective in achieving long-term survival for post-aplastic anemia myeloid neoplasms: the EBMT Severe Aplastic Anemia Report |
|
Haematologica |
Aplastic Anemia |
| Azacitidine to treat measurable residual disease in patients with MDS/AML: final long-term results of the RELAZA2 trial |
|
Blood |
Myelodysplastic Syndromes (MDS) |
| Venetoclax/FluBu2 RIC transplant followed by all-oral venetoclax/decitabine maintenance for poor risk MDS/AML |
|
Blood Advances |
Myelodysplastic Syndromes (MDS) |
| Updates in low/intermediate-risk MDS |
|
The Hematology, ASH Education Program |
Myelodysplastic Syndromes (MDS) |
| The varieties of therapeutic experience: navigating treatment options for patients with PNH |
|
The Hematology, ASH Education Program |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Sequential versus standard conditioning in untreated MDS patients with blasts undergoing allogeneic HSCT |
|
Bone Marrow Transplant |
Myelodysplastic Syndromes (MDS) |
| Real-world clinical outcomes and treatment response in complement inhibitor experienced and naïve PNH patients prescribed pegcetacoplan in Europe and Canada |
|
Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Characterizing clinically significant extravascular hemolysis in adults with PNH on ravulizumab or eculizumab treatment |
|
Blood Advances |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
| Infections in lower-risk myelodysplastic syndromes - prevalence and risk factors: a report from the European MDS Registry |
|
Haematologica |
Myelodysplastic Syndromes (MDS) |
| Optimal timing of allogeneic hematopoietic stem cell transplant in MDS |
|
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
